The present disclosure provides a method for predicting the efficacy of a treatment with an immune checkpoint inhibitor (ICI) on a subject. The present disclosure also provides a method for treating a tumor in a subject on whom the efficacy of the treatment has been proved. The efficacy prediction can be performed on a blood sample of a subject.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
3.
BIOLOGICAL MOVEMENT MEASUREMENT DEVICE AND BIOLOGICAL MOVEMENT MEASUREMENT SYSTEM
A biological movement measurement device according to the present invention comprises: one or more magnetic generators placed at a first site in a living body; one or more magnetic field sensors that are placed at another site different from the first site in the living body, and measure the magnetic field generated by each magnetic generator by means of two or more orthogonal measurement axes; and a signal processing unit that calculates the relative positions of each magnetic field generator and each magnetic field sensor on the basis of the magnetic field measured by each magnetic field sensor.
In order to enable use of novel immunostaining for a pathological diagnosis and research, the invention provides a sample exchange chamber including: a container 2 into which a substrate on which a sample is placed can be introduced; a specific solution inlet 3, which is a staining mechanism that stains the sample; a cleaning liquid inlet 4, which is a cleaning mechanism that cleans the sample; an evacuation port 5, which is an evacuation mechanism that evacuates the container; a drain port 6; and a sterilization mechanism 7 that sterilizes the sample and inside of the container.
Provided is a method for treating a disease in which Hic-5 participates. A composition comprising a Hic-5 inhibitor, said composition being for treating a disease selected from among cardiomegaly, interstitial pneumonia, osteoarthritis, fatty liver and tumor, or for inhibiting vascular invasion of cancer cells.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 9/00 - Drugs for disorders of the cardiovascular system
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
6.
FLAT PLATE FOR MICROSCOPIC SPECIMEN PREPARATION USE, AND METHOD FOR PREPARING MICROSCOPIC SPECIMEN
The purpose of the present invention is to provide a flat plate for microscopic specimen preparation use and a method for preparing a microscopic specimen, neither of which require deparaffinization using xylene. The present invention provides a flat plate for microscopic specimen preparation use, the flat plate comprising a transparent flat plate having molten paraffin adsorption properties. The present invention also provides a method for preparing a microscopic specimen, the method including an adsorption step for melting paraffin attached to a sample and allowing the molten paraffin to be adsorbed on a flat plate for microscopic specimen preparation use comprising a transparent flat plate having molten paraffin adsorption properties.
This living-body monitoring device comprises: an electronic apparatus including a circuit substrate; and a living-body wearing instrument that fixes or seals the electronic apparatus. The circuit substrate has mounted thereon a control unit, a battery, and an antenna. The circuit substrate has length-direction dimensions and width-direction dimensions, and comprises at least one copper foil pattern layer. The antenna is disposed on one length-direction end of the circuit substrate.
H01Q 1/24 - SupportsMounting means by structural association with other equipment or articles with receiving set
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61C 7/00 - Orthodontics, i.e. obtaining or maintaining the desired position of teeth, e.g. by straightening, evening, regulating, separating, or by correcting malocclusions
A61C 8/00 - Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereonDental implantsImplanting tools
An object to allow an automatic discrimination between a super enlarged image and a non-enlarged image in a computer diagnosis assistance system that analyzes a state of an epithelium using an image analysis. An image analyzing device according to this disclosure is the image analyzing device to be connected to an endoscope, and includes a target image determination unit that obtains an image from the endoscope and determines whether or not the image is a target image using a halation region included in the image, and an image analyzing unit that analyzes a state of an epithelium, captured by the endoscope, using the target image when the image is the target image.
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
9.
DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG
A drug containing a compound represented by formula (I) as an active ingredient, used for complications from diabetes.
A drug containing a compound represented by formula (I) as an active ingredient, used for complications from diabetes.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
10.
IMMUNOSTAINING METHOD, SAMPLE EXCHANGE CHAMBER, AND CHARGED PARTICLE BEAM DEVICE
To make a novel immunostaining applicable to pathological diagnoses and studies, provided is a sample exchange chamber that comprises a container 2 into which a substrate carrying a sample thereon can be introduced, a specific solution inlet 3 which is a staining member for staining the sample, a washing liquid inlet 4 which is a washing member for washing the sample, a vacuum exhaust vent 5 which is an exhaustion member for evacuating the container, a waste liquid port 6, and a sterilization member 7 for sterilizing the inside of the container and the sample.
The present invention inactivates viruses in the air and viruses attached to an object as a target to be treated. In this invention, a plant-derived waste containing polyphenols or an extract thereof is irradiated with light to generate hydroxyl radicals, and the hydroxyl radicals generated inactivate viruses included in an object to be treated.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
KAGOSHIMA UNIVERSITY (Japan)
SHOWA UNIVERSITY (Japan)
Inventor
Takasaki Ichiro
Toyooka Naoki
Okada Takuya
Kurihara Takashi
Gouda Hiroaki
Abstract
The present invention pertains to: a compound represented by formula (I) (in the formula, R11-61-61-61-61-6-alkyl amino group, R21-61-61-61-61-6-alkyl amino group, R31-61-61-6-alkyl group, and R43-123-12-hydrocarbon group) or a salt thereof, or a solvate thereof; and an analgesic drug that contains the compound or a salt thereof, or a solvate thereof.
C07D 239/91 - Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
13.
Intraoral sensing apparatus and manufacturing method thereof
The present intraoral sensing apparatus is configured to be installed in an oral cavity, and is provided with an electronic device equipped with electronic components mounted on a circuit board; a first dental resin material which completely covers the electronic device; a second dental resin material which completely covers the first dental resin material; and an intraoral instrument having a first recess in which the electronic device covered with the first dental resin material and the second dental resin material is accommodated.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61C 13/20 - Methods or devices for soldering, casting, moulding or melting
Provided is a method for treating a disease in which Hic-5 participates. A composition comprising a Hic-5 inhibitor, said composition being for treating a disease selected from among cardiomegaly, interstitial pneumonia, osteoarthritis, fatty liver and tumor, or for inhibiting vascular invasion of cancer cells.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
15.
Analgesic drug using PAC1 receptor antagonistic drug
This invention relates to an analgesic drug comprising a compound represented by the following formula (I) or (II),
2 is a hydrogen atom; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
16.
Endoscope observation assistance apparatus and endoscope observation assistance method
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
Inventor
Mori, Yuichi
Kudo, Shin-Ei
Misawa, Masashi
Mori, Kensaku
Abstract
An endoscope observation assistance apparatus includes an image information acquiring part to acquire and display a captured image of a luminal organ captured by the endoscope device on a display, a lesion information acquisition part to detect a predetermined lesion based on the captured image and to acquire lesion information regarding the lesion, a lesion disappearance determination part to track the lesion based on the captured image and the lesion information and to determine whether or not the lesion has disappeared from the captured image, and a notification part to notify a determination result when the lesion disappearance determination part determines that the lesion has disappeared from the captured image. Alternatively, the notification part may notify a lesion detection when a short time period passes after the lesion detection by the lesion information acquisition part.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
The purpose of this disclosure is to automatically discriminate between a super enlarged image and a non-enlarged image using a computer diagnosis assistance system for analyzing the state of the epithelium by image analysis. This image analyzing device (10) is connected to an endoscope (20) and is provided with: a target image determination unit (111) for acquiring an image from the endoscope (20) and determining if the image is a target image using a halation region included in the image; and an image analyzing unit (112) which, when the image is the target image, analyzes the state of the epithelium imaged by the endoscope (20) using the target image.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
Provided is an endoscopic therapy system with which it is possible to prevent generation of perforation without being influenced by an operator's skill. This endoscopic therapy system (1) is for performing treatment on a patient by means of a treatment device while capturing an image of the inside of the patient's body, and is provided with an endoscope unit (2) which acquires imaging data acquired by capturing an image of the inside of the patient's body; a determination unit (3) which makes a determination on the basis of the imaging data acquired by the endoscope unit; a monitor unit (4) which displays an image based on the imaging data; and an electrocautery apparatus (5) which is capable of performing dissection on the patient's body. The determination unit determines, from the condition of the electrocautery apparatus shown in the imaging data, whether or not any danger is involved, and then transmits a warning signal to the monitor unit and/or the electrocautery apparatus in the case where it is determined that there is a danger involved.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
21.
DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
This intraoral organism monitoring device comprises: a sensor; a communication unit for carrying out communication in response to the input of a signal into the sensor; and a mouthpiece that holds the sensor and communication unit, is attached to a crown of a subject, and covers at least a portion of the gums of the subject.
C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
C07C 67/30 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
C07C 67/31 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
24.
Examination assisting method, examination assisting apparatus, and computer-readable recording medium
A non-transitory computer-readable recording medium stores therein an examination assisting program that causes a computer to execute a process including: performing a site detecting process that uses an object detection technique on each of a plurality of ultrasound examination images taken of an examined subject by performing a scan on the examined subject; and displaying a site detection map in which a detection result of each of a plurality of sites included in the examined subject is kept in correspondence with the scan, on a basis of detection results from the site detecting process.
G06T 7/143 - SegmentationEdge detection involving probabilistic approaches, e.g. Markov random field [MRF] modelling
G06T 7/174 - SegmentationEdge detection involving the use of two or more images
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
25.
Anomalousness determination method, anomalousness determination apparatus, and computer-readable recording medium
A non-transitory computer-readable recording medium storing therein an anomalousness determination program that causes a computer to execute a process includes: sensing a region in an object in each of a plurality of ultrasound examination images using an object sensing technique; based on a result of the sensing and a structure of the object, acquiring a result of sensing each of a plurality of regions in the object in each of the ultrasound examination images; and determining anomalousness in the object based on the result of sensing each of the regions in the ultrasound examination images.
NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (Japan)
Inventor
Mori, Yuichi
Kudo, Shin-Ei
Misawa, Masashi
Mori, Kensaku
Abstract
Provided is an endoscope observation assistance device, and the like, which has higher endoscope observation assisting performance and enables doctors to observe a lesion more easily and accurately. This endoscope observation assistance device (100) is provided with: an image information acquisition unit (31) for acquiring images of a lumen organ captured by an endoscope device (40) and displaying the captured images on a display unit (22); a lesion information acquisition unit (32) for detecting a predetermined lesion on the basis of the captured images and acquiring lesion information relating to the lesion; a lesion disappearance determination unit (34) for tracking the lesion on the basis of the captured images and the lesion information and determining whether the lesion has disappeared in a captured image or not; and a notification unit (35) which, when the lesion disappearance determination unit (34) has determined that the lesion has disappeared in a captured image, reports the determination result. The notification unit (35) may report detection of a lesion by the lesion information acquisition unit (32) after the passage of a very short time after the detection.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
in vitroin vitro, said method comprising: (i) a step for culturing an oral ectoderm-containing cellular aggregate under such conditions that the expression of Sox9 and Foxc1 is induced; and (ii) a step for further culturing all or part of the cellular aggregate, that has been cultured in step (i), in a medium containing FGF7 and FGF10.
A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
29.
ANALGESIC DRUG USING PAC1 RECEPTOR ANTAGONISTIC DRUG
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
SHOWA UNIVERSITY (Japan)
Inventor
Kurihara Takashi
Takasaki Ichiro
Toyooka Naoki
Gouda Hiroaki
Abstract
The present invention relates to an analgesic drug containing: a compound represented by formula (I) or (II) (where, R11-61-61-6-haloalkoxy group; R2 is a hydrogen atom; R is an indazolyl group substituted with a halogen atom, a substituted or unsubstituted phenyl group, a pyrazolyl group, or a substituted or unsubstituted aralkyl group.); a salt thereof; or a solvate thereof.
Provided is a cancer detection method, wherein: an amount of amino acids or proteins in a detection region, and an amount of nucleic acids are acquired; the ratio of the acquired amount of amino acids or proteins with respect to the acquired amount of nucleic acids is calculated; and the presence of cancer cells is determined on the basis of a comparison of the calculated ratio and a preset first threshold value. In the cancer detection method, a configuration may be employed such that the amount of amino acids in the detection region is detected as an indicator of the amount of proteins, the amount of nucleobases in the detection region is detected as an indicator of the amount of nucleic acids, and the ratio of the detected amount of amino acids with respect to the detected amount of nucleobases is used as the ratio.
Provided is a dental ultrasonic cleaning device that efficiently cleans teeth or dentures in an oral cavity using ultrasonic waves. A dental ultrasonic cleaning device 1 emits ultrasonic waves through a cleaning-liquid (W1) to the surface of a cleaning-target 26, ultrasonically cleaning it. An ultrasonic horn 24 propagates ultrasonic waves being generated by an ultrasonic-wave transducer 23 and emits them from the vibratory surface 25 provided at the tip-end of the horn 24. A liquid-reserving part 27 is provided, surrounding the vibratory surface 25 of the ultrasonic horn 24, which temporarily reserves the cleaning-liquid (W1) between the vibratory surface 25 and the cleaning-target 26. A cap-member 33 is provided at a certain interval opposite the liquid-reserving part 27. A cleaning-liquid discharge-tube inlet 35 is connected to a vacuum tube 36 within the cap-member 33, allowing the cleaning-liquid W1 used during the ultrasonic cleaning to be vacuumed from the oral cavity, into the cap-member 33, and then discharged through the vacuum tube 36.
This invention is achieved to provide a water-flow ultrasonic oral-cavity cleaning device. In the water-flow ultrasonic oral-cavity cleaning device (1), cleaning liquid (W1) from a cleaning-liquid supplying device (2) is supplied into a transducer case (21) through a supply port (26). Ultrasonic waves (S1) are propagated into the cleaning liquid W1 from an ultrasonic transducer (22) mounted in a transducer mounting part (23) inside the transducer case (21). The water-flow of the cleaning liquid (W1) is collected at the apical-part inside the transducer case (21), and then emitted from the issue (27) into the oral cavity, wherein power supply of 100W or less is supplied to the ultrasonic transducer (22) of 50 mm or less in diameter to propagate the ultrasonic waves (S1) of 100 kHz or more to 3 MHz or less in frequency into the cleaning liquid (W1).
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
SHOWA UNIVERSITY (Japan)
ASUKA ELECTRIC CO.LTD. (Japan)
Inventor
Ino Shuichi
Sato Mitsuru
Yoshimura Shinichi
Abstract
A device for evaluating diabetic peripheral neuropathy is provided with: a footrest (2); a probe (4) which applies a moving stimulus to the sole of a foot; and a probe drive structure (3) which is provided on a base (1) and performs an operation for moving the probe (4) individually in directions orthogonal to each other along the sole of the foot. The device is further provided with: an input switch (5) which is operated by a subject that has perceived the moving stimulus; a drive control unit (51) which controls the drive state of the probe drive structure (3); and a main control unit (B) which evaluates a measured sensation threshold. In the main control unit (B), reference data relating to known sensation thresholds when the moving stimulus is applied to the soles of feet of a group of patients, and age correction factors calculated from sensation threshold standard values based on differences in the ages of the patients are previously stored. The drive control unit (51) controls the drive state of the probe drive structure (3) using the reference data and the age correction factor to execute a primary stimulus application state, and further sequentially execute a secondary stimulus application state and a tertiary stimulus application state, and measures sensation thresholds.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
34.
DENTAL ULTRASONIC CLEANING DEVICE AND METHOD FOR CLEANING TEETH OR DENTURE USING ULTRASOUND
Provided is a dental ultrasonic cleaning device that can efficiently clean teeth or dentures in the mouth using ultrasound. A dental ultrasonic cleaning device (1) emits ultrasonic waves via a cleaning solution (W1) to the surface of a cleaning target (26) to carry out an ultrasonic cleaning. An ultrasonic horn (24) propagates ultrasonic waves generated by an ultrasonic vibrator (23) and outputs ultrasonic waves from a vibration surface (25) provided to a horn distal end side. A solution-collecting section (27) is provided so as to surround the vibrating surface (25) of the ultrasonic horn (24). The solution-collecting section (27) temporarily collects the cleaning solution (W1) between the surface of the cleaning target (26) and the vibrating surface (25). A cap member (33) is arranged facing the solution-collecting section (27) at a predetermined spacing. A suction tube (36) having a solution intake (35) is connected to the inside the cap member (33). The cleaning solution (W1), having been used for the ultrasonic cleaning, is suctioned in from the cap member (33) and discharged to outside of the mouth via the suction tube (36).
Provided is a water jet spray nozzle, a water jet spray device, a gastrointestinal tract cleaning device, and a gastric wall cleaning device, whereby the cleaning performance with respect to water pressure can be increased, and when used to clean the gastric wall, gastric mucus can be effectively removed without damaging stomach tissue such as the gastric mucosa. A water jet spray nozzle (11) comprising: a flow path (11a) that includes, in order toward the distal end, a small-diameter portion (21) having an inner diameter that decreases from the upstream side, an expanded portion (22) having an inner diameter larger than that of the small-diameter portion (21), and a jet orifice (23) having an inner diameter smaller than that of the expanded portion (22). When water flows at a pressure of 0.2 to 0.6 MPa to the flow path (11a), the water collects in the expanded portion (22) and a cavitation bubble is generated heading from the small-diameter portion (21) toward the expanded portion (22). The inner diameter of the small-diameter portion (21) is 0.5 to 0.7 mm, and the inner diameter of the jet orifice (23) is 1 to 1.3 times larger than the inner diameter of the small-diameter portion (21).
A61M 3/00 - Medical syringes, e.g. enemataIrrigators
A61C 17/02 - Rinsing or air-blowing devices, e.g. using fluid jets
A61C 17/00 - Devices for cleaning, polishing, rinsing or drying teeth, teeth cavities or prosthesesSaliva removersDental appliances for receiving spittle
The present invention addresses the problem of providing a chewing-enhanced food that has the hardness, viscosity, and other characteristics suitable for the mouth of a small child aged 1 year to five years 11 months, and particularly a young child aged about 18 months who has been weaned and is using teeth for chewing. This chewing-enhanced food contains: at least one main ingredient selected from wheat flour, rice flour, starch, or other powder; and an auxiliary ingredient composed of sorbitol and/or glycerol. This chewing-enhanced food preferably has a breaking stress, breaking strain, brittleness stress, and cohesiveness that are within a predetermined range.
A23G 3/50 - Sweetmeats, confectionery or marzipanProcesses for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
[Problem] To provide a flow-type ultrasonic oral cavity washing device capable of reliably and efficiently washing the oral cavity. [Solution] In a flow-type ultrasonic oral cavity washing device (1), washing fluid (W1) of a washing fluid supply device (2) is supplied to inside a transducer casing (21) through a supply port (26). Ultrasonic waves (S1) are propagated into the washing fluid (W1) from an ultrasonic transducer (22) mounted in a transducer mounting section (23) inside the transducer casing (21). The flow of washing fluid (W1) is collected at the tip portion inside the transducer casing (21), and then output into the oral cavity from an outflow port (27). In the flow-type ultrasonic oral cavity washing device (1), power of 100W or less is supplied to the ultrasonic transducer (22) that is 50mm or less in diameter, and ultrasonic waves (S1) having a frequency of at least 100kHz but less than 3MHz are propagated into the washing fluid (W1).
[Problem] To provide a device for washing oral cavity and a method for washing oral cavity, whereby stains such as plaque and dental calculus can be effectively removed even from a narrow space such as a gap between teeth or a gap of an implant. [Solution] A device for washing oral cavity, said device comprising a cover (11) provided with an injection hole (11a) and a discharge hole (11b), wherein the cover (11) covers a tooth (1) while leaving a space between the cover (11) and the tooth (1) so that water can be held in the space. To the injection hole (11a), an injection means (12), which is provided with a channel (24a) connected to the space between the tooth (1) and the cover (11), is attached. The injection means (12) is configured so that cavitation bubbles can be generated when water flows in the channel (24a) toward the space and the thus generated cavitation bubbles are injected toward the inside of the cover (11). The channel (24a) has a small diameter part (24b) with a channel diameter being smaller than the channel diameter in the upstream side and an enlarged part (24c) with a channel diameter being larger than the channel diameter in the small diameter part (24b). A discharge means (13) is provided so that water within the space between the tooth (1) and the cover (11) is discharged through the discharge hole (11b).
An exercise model (11) for a small intestine endoscope, allowing the user to familiarize with the practical operation of an endoscope (38) by enabling the user to obtain a feeling similar to the feeling when the endoscope (38) is actually inserted into the small intestine (34) of a living body (30). The exercise model (11) is provided with elongated elastic bodies (32) for respectively applying elastic forces to portions of a simulated small intestine (13). One end side of each elongated elastic body (32) is mounted to each first mounting section (27) on the simulated small intestine (13) side. The other end side of each elongated elastic bodies (32) is mounted to second mounting sections (33, 57) on the case (12) side.
G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
National University Corporation Tokyo University of Agriculture and Technology (Japan)
SHOWA UNIVERSITY (Japan)
TMS Co., Ltd. (Japan)
Inventor
Honda, Kazuo
Hashimoto, Terumasa
Shibata, Keita
Hasegawa, Keiko
Hasumi, Keiji
Abstract
Disclosed is a cytoprotective agent which contains a triprenyl phenol compound represented by general formula (I) as an active ingredient, and which is used for ischemic disorders. In the formula, X represents -HCY-C(CH3)2Z; Y and Z each independently represents -H or -OH, or alternatively, Y and Z combine together to form a single bond; and R represents a hydrogen atom or a substituent that has a molecular weight of 1000 or less.)
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
41.
OSTEOGENESIS PROMOTER COMPRISING [4-(METHYLTHIO)PHENYLTHIO]METHANEBISPHOSPHONIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT
Disclosed are: a compound which can be produced through a chemical synthesis at low cost, has an excellent osteogenesis-promoting activity, has high affinity for a bone, and can be applied without the need of any special DDS; and a method for promoting osteogenesis by administering the compound and applying the promotion of osteogenesis to the formation or regeneration of a bone. Specifically disclosed are: an osteogenesis promoter or a pharmaceutical composition comprising [4-(methylthio)phenylthio]methanebisphosphonic acid, which is one of bisphosphonic acids, or a pharmaceutically acceptable salt thereof as an active ingredient; and a method for promoting osteogenesis, which comprises administering the osteogenesis promoter or the pharmaceutical composition to a subject to be treated.
The object aims to form and maintain a cell, a tissue or an organ induced by differentiation. Disclosed is a composition for inducing the differentiation of a cell capable of being differentiated in a given direction to thereby produce a cell, a tissue or an organ through the further induction of the differentiation in the given direction. The composition comprises NELL-1 or a substance which can be altered so as to act as NELL-1 upon the differentiation. Also disclosed is a composition for maintaining a cell, a tissue or an organ produced by the induction of the differentiation.
It is intended to provide an artificial skin which does not contain an animal-derived material or a pathogen and is excellent in biocompatibility. As a means for resolution, a method for producing an artificial skin comprising the steps of: (A) forming a dermal layer by solidifying a mixture of dermal fibroblasts and a peptide hydrogel having a fibrous structure; and (B) forming an epidermal layer by seeding and culturing skin keratinocytes on the dermal layer obtained in the step (A) is provided.
It is intended to provide a medicine capable of acting exclusively in a site where an osteoblast is present and quickly inducing osteogenesis associated with chondrogenesis in the same manner as in natural healing without causing a side effect such as serious inflammation in vivo. The above problem has been solved by providing a bone therapeutic agent which contains NELL1 for treating bone without causing inflammation. The bone therapeutic agent as described above is usable for repairing bone defect after lesion curettage or excision, prolonging bone fracture healing, pseudo-joint formation, distraction osteogenesis, artificial joint replacement, spinal fusion, cartilage transplantation, transplantation into jaw cleft, repairing bone defect caused by wound, repairing bone defect after craniotomy, alveolar ridge formation, maxillary sinus floor lifting, alveolar bone regeneration, jaw bone regeneration around artificial dental root, and so on.
NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (Japan)
Inventor
Watanabe, Takuya
Shichiri, Masayoshi
Abstract
Disclosed are: a prophylactic or therapeutic agent for an arteriosclerotic disease; and a method and a reagent for detecting an arteriosclerotic disease. Specifically disclosed are: a therapeutic agent for an arteriosclerotic disease, which comprises thallusin-α as an active ingredient; a therapeutic agent for an arteriosclerotic disease, which comprises an antagonist of thallusin-β as an active ingredient; and a method for detecting an arteriosclerotic disease, which comprises measuring thallusin-α in a biological sample.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
46.
AGENT FOR AMELIORATION OF OPHTHALMIC CIRCULATORY DISORDER
Disclosed is an agent for ameliorating an ophthalmic circulatory disorder for orally administering limaprost to a patient with the ophthalmic circulatory disorder in an amount of 5 to 50 &mgr;g per day for a period of 2 to 72 weeks. The agent can be administered orally to ameliorate the ophthalmic circulatory disorder, and treat a symptom induced by the ophthalmic circulatory disorder and/or prevent the progress of the symptom. Further, the agent can shorten the period required for disappearance of the hemorrhage of the optic fundus associated with the ophthalmic circulatory disorder and also shorten the period required for the recovery of decreased visual acuity and/or the amelioration of a visual field disorder.
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Disclosed s a novel agent for promoting the secretion of tear. The agent comprises a peptide capable of acting on a PAC1 receptor or a pharmaceutically acceptable salt thereof.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Method for cryopreserving microencapsulated living animal cells enclosed in immunoisolation membranes, such microencapsulated living animal cells in immunoisolation membranes, and biohybrid artificial organ modules using such microencapsulated living animal cells in immunoisolation membranes
A method is disclosed for cryopreserving living animal cells in immunoisolation membranes, including: (1) cutting out a living organ from an animal, (2) digesting the cutout organ into the discrete living animal cells and separating the discrete cells, (3) suspending the separated cells in a solution of sodium chloride containing sodium alginate and collagen, (4) forming microcapsules of the living animal cells by using the resulting suspension, (5) forming immunoisolation membranes around outer surfaces of the microcapsules of the living animal cells by covering the outer surfaces with alginate-(poly-L-lysine) and thereby obtaining the living animal cells enclosed in the immunoisolation membranes, (6) suspending the resulting living animal cells enclosed in the immunocapsules in a cell damage-preventing solution, and (7) immediately freezing the thus obtained suspension with liquid nitrogen.
patents
